Hydroxytyrosol Improved Complex Attention in Adults Aged 51 to 82

Hydroxytyrosol, the most abundant polyphenol in extra virgin olive oil, is increasingly studied for its potential role in brain health and cognitive aging. A 2023 randomized controlled trial published in Nutrients tested whether a high-dose hydroxytyrosol supplement could improve cognitive function in adults aged 51 to 82 -- and found significant improvements in complex attention after just 12 weeks.

Why This Study Matters

Most research on olive polyphenols and brain health is observational -- it shows that people who eat more olive oil tend to have better cognitive outcomes, but it can't prove the polyphenols caused the improvement. The handful of intervention trials that exist usually test olive oil as a whole food or as part of a broader Mediterranean diet, making it impossible to isolate which component is doing the work.

This 2023 trial from the University of Tsukuba took a different approach. Researchers gave older adults a concentrated olive-derived supplement standardized to a high dose of hydroxytyrosol -- 162 times the concentration found in regular olive oil -- and measured cognitive function using a validated computerized test battery before and after 12 weeks. The question was specific: does hydroxytyrosol, at a defined daily dose, improve measurable cognitive performance in people aged 51 to 82?

The answer, at least for one critical cognitive domain, was yes.

How It Was Designed

This was a randomized, double-blind, placebo-controlled trial conducted between April and June 2022 in Tsukuba City, Japan. Seventy-two participants (mean age 69.5, 73.6% women) were split evenly between an active group receiving 32.4 mg/day of hydroxytyrosol and a placebo group receiving cornstarch capsules dipped in olive oil. Neither participants nor researchers knew who received what -- blinding management was handled by an independent corporation.

Cognitive function was assessed using Cognitrax, a standardized computerized battery that measures 11 distinct cognitive domains including memory, attention, processing speed, executive function, and reaction time. Scores are normalized against a large reference population aged 7 to 90, and reaction times are recorded with millisecond precision. Compliance was verified by supplement return counts and was notably high at 97.2%. Baseline characteristics -- age, BMI, blood pressure, MMSE scores, and medication use -- were well-matched between groups with no significant differences.

What They Found

The primary finding was a significant time-by-group interaction for complex attention -- the only cognitive domain where the supplement group improved significantly more than placebo:

Cognitive Domain	HT Group Change	Placebo Change	Interaction p	What It Measures
Complex Attention	-5.6 points (d = 0.36)	-0.9 points (d = 0.08)	0.049	Sustained focus, error detection, vigilance
Processing Speed	+3.5 points (d = 0.35)	+2.5 points (d = 0.20)	0.542	Speed of information processing
Executive Function	+8.0 points (d = 0.36)	+4.9 points (d = 0.22)	0.248	Planning, decision-making, task switching
Cognitive Flexibility	+6.9 points (d = 0.29)	+4.9 points (d = 0.21)	0.441	Ability to shift between mental tasks
Psychomotor Speed	+6.2 points (d = 0.21)	+12.5 points (d = 0.38)	0.255	Motor response speed
Reaction Time	-18.3 ms (d = 0.12)	-20.0 ms (d = 0.17)	0.857	Speed of response to stimuli

Lower scores indicate better performance for complex attention and reaction time. Higher scores indicate better performance for all other domains. Only complex attention showed a statistically significant group interaction (p = 0.049).

Reading the Results

Complex attention was the standout finding. This domain measures sustained vigilance, error detection, and the ability to maintain focus over time -- the kind of attention that degrades earliest in age-related cognitive decline. The hydroxytyrosol group improved from a score of 19.1 to 13.5 (lower is better), a reduction of 5.6 points. The placebo group barely moved, going from 12.2 to 11.3. The simple main effect for the supplement group was highly significant (p < 0.001) while the placebo group showed no significant change (p = 0.572). This was the only domain with a statistically significant interaction between time and group assignment.

Several other domains showed meaningful effect sizes in the supplement group -- executive function (d = 0.36), processing speed (d = 0.35), and cognitive flexibility (d = 0.29) -- though none reached significance for the group interaction. Both groups improved over time in these areas, likely due to practice effects from taking the same test twice. What's notable is the consistent pattern: the hydroxytyrosol group showed numerically larger improvements in attention-related and executive domains, while the placebo group showed larger improvements in pure motor tasks.

Age mattered. Subgroup analysis showed that older adults (ages 61 to 82) derived greater benefit from the supplement than middle-aged adults (ages 51 to 60). This aligns with the biological logic: people with more age-related cognitive decline have more room for a neuroprotective compound to demonstrate an effect.

What Didn't Change

Memory was unaffected. Composite memory, verbal memory, and visual memory showed no significant differences between groups, and the effect sizes in the hydroxytyrosol group were negligible (d = 0.00 to 0.05). Simple attention also did not change. The supplement's effects in this trial were specific to attention-executive domains -- the functions most associated with daily cognitive performance and early age-related decline -- rather than memory encoding or recall.

Broader Context

The connection between extra virgin olive oil consumption and cognitive health has been established primarily through the PREDIMED trial, where participants randomized to a Mediterranean diet supplemented with EVOO showed significantly better cognitive function over 6.5 years compared to controls. The European Food Safety Authority (EFSA) has authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage, and oxidative stress is increasingly recognized as a key driver of neurodegeneration.

What distinguishes this trial is the delivery format. Rather than testing olive oil as a food, the researchers used a concentrated olive-derived supplement delivering 32.4 mg/day of hydroxytyrosol -- an approach that isolates the polyphenol from the broader dietary matrix. The result is a cleaner test of whether hydroxytyrosol specifically, rather than olive oil generally, can influence cognitive performance. At 72 participants over 12 weeks, it's a proof-of-concept study, not a definitive answer. But it's one of the first randomized controlled trials to directly link hydroxytyrosol supplementation to a measurable improvement in human cognitive function.

Related Research

Continue exploring olive oil and polyphenol science:

• Olive Oil and Brain Health: 66% Lower Cognitive Impairment Risk in PREDIMED Trial
• Olive Oil Linked to 28% Lower Dementia Death in 92,383 Adults
• Three-City Study: Olive Oil Use Linked to Better Cognitive Function in Elderly

Source: View the original study on PubMed

Olivea's Dosage

This trial used 32.4 mg/day of hydroxytyrosol from an olive-derived supplement. Each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving. Our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.